StockData
TransMedics Group, Inc. logo

TransMedics Group, Inc. (TMDX) company profile

TMDXNasdaqElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 14/3029% below fair value
$93.91+1.70 (+1.84%)

Close on Nov 17, 2026Market cap $3.26BP/E 24.4Yield 0.00%

About TransMedics

Electromedical & Electrotherapeutic Apparatus, SIC 3845

TransMedics is a medical technology company that develops systems and services for organ transplantation. Its core product platform is the Organ Care System, a portable warm perfusion device designed to preserve donor hearts, lungs, and livers in a functioning state outside the human body. The system comprises an electromechanical console, single-use perfusion sets, and nutrient solutions. The company also offers the National OCS Program, providing outsourced organ procurement, perfusion management, and air and ground transport logistics. Its primary customers are hospital transplant programs and academic medical centers.

The company is headquartered in Andover, Massachusetts, with plans to transition its headquarters to Somerville, Massachusetts. It maintains an aircraft maintenance hub in Dallas, Texas, and operates a fleet of 22 fixed-wing aircraft across the United States. Internationally, the company conducts research and development in Mirandola, Italy, and maintains distribution, commercial, and logistics operations in Europe. As of December 31, 2025, the company employed 898 people worldwide, the majority of whom were full-time personnel located in the United States.

Summary of the business section of TransMedics's latest annual report, written by StockData.

Company profile

Company

Legal name
TransMedics Group, Inc.
Founded
2021
Headquarters
Andover, MA
Address
200 Minuteman Road 01810
Phone
(978) 552-0900
Employees
898, Dec 31, 2025
Industry
Electromedical & Electrotherapeutic Apparatus
Incorporated in
Massachusetts
Fiscal year ends
December 31
Auditor
PricewaterhouseCoopers LLP, Boston, Massachusetts

Stock & identifiers

Ticker
TMDX
Exchange
Nasdaq
IPO date
May 2, 2019
Shares outstanding
35M, Jul 30, 2026
Public float
$4.43B, Jun 30, 2025
Filer category
Large accelerated filer
SEC CIK
1756262
CUSIP
89377M109
ISIN
US89377M1099
FIGI
BBG00NZ6J685
Share class FIGI
BBG00NZ6J701
LEI
549300060GVOSMWARH50
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Waleed H. HassaneinPresident & CEO, Director666,102
Fernando N. AraujoSee Remarks22,969
Nicholas CorcoranSee remarks41,558
Gerardo HernandezChief Financial Officer31,935
Matthew S. ForsythSee Remarks15,409
Anil P. RanganathSee remarks13,091
Giovanni CecereChief Commercial Officer7,975
Tamer I. KhayalChief Commercial Officer36,042
James R. TobinDirector158,068
David WeillDirector16,392
Thomas J. GundersonDirector16,642
Edward M. BasileDirector5,788
Stephanie LovellDirector5,788
Edwin KaniaDirector309,874
Merilee RainesDirector6,981

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$10.92M$26.17M$2.41M$611$99
FY2024$8.20M$9.63M$2.98M$313$81
FY2023$6.76M$12.84M$2.49M$397$82
FY2022$3.29M$25.22M$958.88K$310$77
FY2021$7.37M$5.17M$1.44M$96$96
FY2020$2.39M$2.66M$928.50K$105$130

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOption awardsIncentive payOtherTotalvs. prior year
Waleed H. Hassanein, M.D.
President and Chief Executive Officer
$776.92K$4.36M$4.36M$1.40M$14.45K$10.92M+33%
Gerardo Hernandez
Chief Financial Officer
$488.46K$271.54K$271.12K$525.00K$14.45K$1.57M-11%
Tamer Khayal, M.D.
Former Chief Commercial Officer
$496.32K$1.36M$1.36M$525.80K$14.45K$3.75M+22%
Nicholas Corcoran
Senior Vice President of Supply Chain and Operations
$451.73K$977.57K$976.17K$399.66K$14.45K$2.82M+3%
Anil Ranganath
Former Senior Vice President, General Counsel and Corporate Secretary
$412.31K$434.49K$433.82K$208.00K$14.45K$1.50M+153%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
May 2, 2019
Offer price
$16.00
Securities offered
5,690,000
Gross proceeds
$91.04M
Exchange
Nasdaq
First trading day
May 2, 2019
First-day close
$22.36+39.8%
Lock-up ends (est.)
Oct 29, 2019

“The initial public offering price is $16.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we employed 898 people globally, most of whom were full-time and located in the United States.”

Corporate history

Events identified from SEC filings

DateEventDetails
Oct 6, 2025Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Feb 21, 2025Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Jan 14, 2025Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Dec 9, 2024Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Sep 11, 2024Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Jul 29, 2024Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Jul 2, 2024Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Mar 12, 2024Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Feb 6, 2024Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Jan 29, 2024Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Jan 2, 2024Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Dec 19, 2023Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Nov 13, 2023Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Sep 22, 2023Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Sep 12, 2023Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Sep 5, 2023Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
May 2, 2019IPOInitial public offering priced (424B4 prospectus)
May 1, 2019ListingRegistration of securities on an exchange (Form 8-A)

See a number that looks wrong?